We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Bayer Aktiengesellschaft (PK) | USOTC:BAYRY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 7.60 | 7.59 | 7.68 | 7.69 | 7.59 | 7.66 | 2,551,609 | 21:30:14 |
From May 2019 to May 2024
By Giulia Petroni
Bayer AG said Tuesday that it appointed Christian Rommel as the new head of research and development at its pharmaceuticals division, effective from Feb. 1.
The German pharmaceutical and chemical conglomerate said Mr. Rommel will succeed Joerg Moeller, who decided to leave the company effective Dec. 31 to pursue other career opportunities.
Mr. Rommel will serve on the pharmaceuticals executive committee and report to Stefan Oelrich, the division's president and a member of the board of management.
Prior to joining Bayer, Mr. Rommel served as senior vice president and global head of oncology research and early development at Hoffmann-La Roche AG.
Write to Giulia Petroni at giulia.petroni@wsj.com
(END) Dow Jones Newswires
October 27, 2020 09:31 ET (13:31 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Bayer Aktiengesellschaft (PK) Chart |
1 Month Bayer Aktiengesellschaft (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
